Tweet
October 16, 2009, State College PA SoftGenetics LLC announced the capability of performing analysis and identification of genetic materials for Drug Efficacy Studies and infectious agents such as Bacterial infections and viruses.
Early identification of an infectious agent can lead to a targeted treatment. Fast identification of novel pathogens- new viruses, bacteria, and other microorganisms- such as swine flu and Methicillin-resistant Staphylococcus aureus (MRSA) will speed up vaccine and new drug development. Drug efficacy studies are becoming easier through the use of Metagenomic analysis of viral, bacterial and human sequences. The viral and bacterial concentration can be determined from the sequence reads after human background is subtracted using NextGENe software.
Dr. Jonathan Liu, SoftGenetics VP of Development indicated “that next generation sequencing technologies such as Roche 454 SequencingTM, Illumina Genome Analyzer and Applied Biosystems SOLiDTM system make it possible to obtain millions of reads in a single run. In the above applications, the human substrate is recognized by the software’s whole human genome reference methodology and removed from the sequences. The remaining sequences are then aligned to multiple bacteria or viral genomes to provide rapid identification of the infectious agents.”
Complete information on NextGENe, this and other applications for 2nd generation sequence analysis, a request is available at www.softgenetics.com. Interested parties may request a 30-day trial via email: [email protected]
Early identification of an infectious agent can lead to a targeted treatment. Fast identification of novel pathogens- new viruses, bacteria, and other microorganisms- such as swine flu and Methicillin-resistant Staphylococcus aureus (MRSA) will speed up vaccine and new drug development. Drug efficacy studies are becoming easier through the use of Metagenomic analysis of viral, bacterial and human sequences. The viral and bacterial concentration can be determined from the sequence reads after human background is subtracted using NextGENe software.
Dr. Jonathan Liu, SoftGenetics VP of Development indicated “that next generation sequencing technologies such as Roche 454 SequencingTM, Illumina Genome Analyzer and Applied Biosystems SOLiDTM system make it possible to obtain millions of reads in a single run. In the above applications, the human substrate is recognized by the software’s whole human genome reference methodology and removed from the sequences. The remaining sequences are then aligned to multiple bacteria or viral genomes to provide rapid identification of the infectious agents.”
Complete information on NextGENe, this and other applications for 2nd generation sequence analysis, a request is available at www.softgenetics.com. Interested parties may request a 30-day trial via email: [email protected]